MERIT Study - Mistral Percutaneous Mitral Valve Repair FIM Study

Mitral Valve Regurgitation Clinical Trial

— MERIT  

Official title:

MERIT Study - Mistral Percutaneous Mitral Valve Repair FIM Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02948231
• Other study ID #: CL-133
• Status: Completed
• Phase: N/A
• Start date: June 25, 2016
• Est. completion date: February 2022

Study information

• Verified date: February 2022
• Source: Mitralix
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Mitral Regurgitation. The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.

Description:

The study is designed to clinically demonstrate device acute safety (Primary Endpoint) along with longer FU device safety and effectiveness evaluation (Secondary Endpoint). The main objectives of the study are : - Evaluate the Acute safety of the implanted Mistral device post procedure and at 30 day follow up period. - Evaluate the long term Safety of the device (3 and 6 months follow up). - Demonstrate effectiveness of the Mistral device in improving MR. Primary endpoints: • Safety: Acute safety. Rate of device related SAE including device related mortality, stroke, MI, cardiac tamponade, surgery for failed percutaneous repair and non-elective cardiovascular surgery to treat an adverse event. At discharge and 30 days. Secondary endpoints: - • Safety: Safety at 3 and 6 months. Rate of SAEs and device related SAEs at 3, 6 and 12months. - Effectiveness: MR reduction post-procedure, at discharge and 30 days, 3 and 6 and 12 months. Improved NYHA class and 6MWT distance at 30 days, 3 and 6 and 12 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4
• Est. completion date: February 2022
• Est. primary completion date: January 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject is willing and able to comply with all required follow-up evaluations
• Genders eligible for the study: Both genders
• Subject has functional MR of grade 3+ or more
• Subject has left ventricular ejection fraction (LVEF) >20 % and < 40%.
• No contraindications to trans-septal puncture
• Subject is of functional class 3 or more (NYHA)
• The subject is high risk to undergo MV surgery.
• Subject is excluded from other standard of care procedures as determined by center heart team.
• Patients with femoral veins enabling catheterization with 12Fr catheters
• Life expectancy = 1 year

Exclusion Criteria:

• Mitral Stenosis = moderate
• Aortic Stenosis/Insufficiency > moderate
• Subvalvular calcification or calcification of the chordae.
• Subject has a prosthesis valve in the mitral position
• Transcatheter aortic valve replacement (TAVR) within 30 days prior to subject registration
• Subject has a history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within the past 3 months.
• Subject has a history of a myocardial infarction (MI) in the past 3 months
• Subject refuses blood transfusion or surgical valve replacement.
• Subject has had a percutaneous interventional or other invasive cardiac or peripheral procedure = 7 days of the index procedure
• Subject has a history of, or has active endocarditis
• Subject has echocardiographic evidence of intra-cardiac mass, thrombus, vegetation or soft-mobile deposits
• Subject is in acute pulmonary edema.
• Subject has hemodynamic instability requiring inotropic or mechanical support.
• Subject has a known hypersensitivity or contraindication to anticoagulant or antiplatelet medication
• Subject has renal insufficiency as evidenced by a serum Creatinine > 3.0mg/dL.
• Subject has ongoing infection or sepsis
• Subject has blood dyscrasias (leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy)
• Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within the past 3 months prior to the index procedure
• Subject requires emergency surgery for any reason
• Subject has a known allergy to Nitinol alloys, 316L\304 stainless steel.
• Pregnant or lactating women.
• Patients being dependent upon the sponsor or upon the investigator or upon the investigational site.
• Subject has a known contrast media allergy
• Presence of high degree atrio-ventricular block (2nd or 3rd degree A-V block), or the presence of tri-fascicular block
• According to investigator on site the patient is suffering from a severe end stage disease (e.g. malignancy, severe pulmonary disease, liver disease, renal failure) and has a life expectancy of less than 1 year.

Related Conditions & MeSH terms

• Mitral Valve Insufficiency
• Mitral Valve Regurgitation

Intervention

Device:
• Mistral implantation
Mistral Implant is implanted in the Mitral valve

Locations

Country	Name	City	State
Belgium	ZNA Middelheim	Antwerpen

Sponsors (1)

Lead Sponsor	Collaborator
Mitralix

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety: Acute safety. Rate of device related SAE including device related mortality, stroke, MI, cardiac tamponade, surgery for failed percutaneous repair and non-elective cardiovascular surgery to treat an adverse event.		Until hospital discharge - up to 5 days post procedure day
Primary	Safety: Acute safety. Rate of device related SAE including device related mortality, stroke, MI, cardiac tamponade, surgery for failed percutaneous repair and non-elective cardiovascular surgery to treat an adverse event.		at 30 days post-procedure
Secondary	Safety: Rate of device related SAE		at 3 months post procedure
Secondary	Safety: Rate of device related SAE		at 6 months post procedure
Secondary	Safety: Rate of device related SAE		at 12 months post procedure
Secondary	Effectiveness: MR Grade reduction.		Post procedure (1 hour after implant device has been implanted)
Secondary	Effectiveness: MR Grade reduction.		Until hospital discharge - up to 5 days post procedure day
Secondary	Effectiveness: MR Grade reduction.		at 30 days post procedure
Secondary	Effectiveness: MR Grade reduction.		at 3 months post procedure
Secondary	Effectiveness: MR Grade reduction.		at 6 months post procedure
Secondary	Effectiveness: MR Grade reduction.		at 12 months post procedure
Secondary	Effectiveness: NYHA class (categorization of heart failure extent).		Post procedure (1 hour after implant device has been implanted)
Secondary	Effectiveness: NYHA class (categorization of heart failure extent)		Until hospital discharge - up to 5 days post procedure day
Secondary	Effectiveness: NYHA class (categorization of heart failure extent)		at 30 days post procedure
Secondary	Effectiveness: NYHA class (categorization of heart failure extent)		at 3 months post procedure
Secondary	Effectiveness: NYHA class (categorization of heart failure extent)		at 6 months post procedure
Secondary	Effectiveness: NYHA class (categorization of heart failure extent)		at 12 months post procedure
Secondary	Effectiveness: 6MWT distance.		Post procedure (1 hour after implant device has been implanted)
Secondary	Effectiveness: 6MWT distance.		Until hospital discharge - up to 5 days post procedure day
Secondary	Effectiveness: 6MWT distance.		at 30 days post procedure
Secondary	Effectiveness: 6MWT distance.		at 3 months post procedure
Secondary	Effectiveness: 6MWT distance.		at 6 months post procedure
Secondary	Effectiveness: 6MWT distance.		at 12 months post procedure